Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19

Detalles Bibliográficos
Autores principales: Girardin, François, Manuel, Oriol, Marzolini, Catia, Buclin, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958820/
https://www.ncbi.nlm.nih.gov/pubmed/35358684
http://dx.doi.org/10.1016/j.cmi.2022.03.030
Descripción
Sumario:

Ejemplares similares